Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours

NCT02482311 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02482311
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02482311 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
July 1, 2015
Completion date
August 22, 2019
Enrollment
92 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer, tnbc, sclc, other solid tumours